These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

392 related items for PubMed ID: 25095710

  • 1. Intensive plasmapheresis and intravenous immunoglobulin for treatment of antibody-mediated rejection after kidney transplant.
    Ruangkanchanasetr P, Satirapoj B, Termmathurapoj S, Namkhanisorn K, Suaywan K, Nimkietkajorn V, Luesutthiviboon L.
    Exp Clin Transplant; 2014 Aug; 12(4):328-33. PubMed ID: 25095710
    [Abstract] [Full Text] [Related]

  • 2. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
    Zheng J, Xue W, Qing X, Jing X, Hou J, Tian X, Guo Q, He X, Cai J.
    Clin Transpl; 2014 Aug; ():223-30. PubMed ID: 26281149
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Late antibody-mediated rejection in renal allografts: outcome after conventional and novel therapies.
    Gupta G, Abu Jawdeh BG, Racusen LC, Bhasin B, Arend LJ, Trollinger B, Kraus E, Rabb H, Zachary AA, Montgomery RA, Alachkar N.
    Transplantation; 2014 Jun 27; 97(12):1240-6. PubMed ID: 24937198
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Multimodal therapy with combined plasmapheresis, photoapheresis, and intravenous immunoglobulin for acute antibody-mediated renal transplant rejection: a 2-year follow-up.
    Lai Q, Pretagostini R, Gozzer M, Cinti P, Meo D, Vita F, Shafii Bafti M, Poli L, Novelli G, Rossi M, Girelli G, Berloco PB.
    Transplant Proc; 2011 May 27; 43(4):1039-41. PubMed ID: 21620047
    [Abstract] [Full Text] [Related]

  • 7. Clinical outcomes of ABO-incompatible kidney transplant with rituximab and double-filtration plasmapheresis.
    Han S, Hwang E, Park S, Park U, Kim H, Cho W.
    Exp Clin Transplant; 2014 Oct 27; 12(5):401-4. PubMed ID: 25299367
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Kidney transplant in highly sensitized patients after desensitization with plasmapheresis and low-dose intravenous immunoglobulin.
    Yuan XP, Wang CX, Gao W, Fu Q, He XS.
    Exp Clin Transplant; 2010 Jun 27; 8(2):130-5. PubMed ID: 20565369
    [Abstract] [Full Text] [Related]

  • 11. Outcomes of combination therapy for chronic antibody-mediated rejection in renal transplantation.
    Kim MG, Kim YJ, Kwon HY, Park HC, Koo TY, Jeong JC, Jeon HJ, Han M, Ahn C, Yang J.
    Nephrology (Carlton); 2013 Dec 27; 18(12):820-6. PubMed ID: 24033843
    [Abstract] [Full Text] [Related]

  • 12. Clinicopathologic analysis of acute vascular rejection cases after renal transplantation.
    Shimizu T, Tanabe T, Omoto K, Ishida H, Tanabe K.
    Transplant Proc; 2012 Jan 27; 44(1):230-5. PubMed ID: 22310621
    [Abstract] [Full Text] [Related]

  • 13. Long-term outcomes of kidney transplantation across a positive complement-dependent cytotoxicity crossmatch.
    Riella LV, Safa K, Yagan J, Lee B, Azzi J, Najafian N, Abdi R, Milford E, Mah H, Gabardi S, Malek S, Tullius SG, Magee C, Chandraker A.
    Transplantation; 2014 Jun 27; 97(12):1247-52. PubMed ID: 24854670
    [Abstract] [Full Text] [Related]

  • 14. Bortezomib use in chronic antibody-mediated allograft dysfunction: a report of three cases.
    Cooper JE, Wiseman AC, Chan L.
    Clin Transpl; 2009 Jun 27; ():455-9. PubMed ID: 20524314
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Management of Chronic Active Antibody-Mediated Rejection in Renal Transplant Recipients: Single-Center Experience.
    Nair P, Gheith O, Al-Otaibi T, Mostafa M, Rida S, Sobhy I, Halim MA, Mahmoud T, Abdul-Hameed M, Maher A, Emam M.
    Exp Clin Transplant; 2019 Jan 27; 17(Suppl 1):113-119. PubMed ID: 30777534
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Highly Sensitized Patients: Miami Transplant Institute Experience.
    Mattiazzi AD, Centeno A, Amador A, Fernandez-Bango C, Scowby CD, O'Rourke M, Hill-Matthie T, Patel R, Barrios F, Ruiz P, Chen L, Saghesima J, Ciancio G, Burke GW, Goldstein M, Chandar J, Contreras G, Roth D, Kupin W, Guerra G, Vianna R.
    Clin Transpl; 2014 Jan 27; ():171-8. PubMed ID: 26281142
    [Abstract] [Full Text] [Related]

  • 19. Reduction of alloantibodies via proteasome inhibition in cardiac transplantation.
    Patel J, Everly M, Chang D, Kittleson M, Reed E, Kobashigawa J.
    J Heart Lung Transplant; 2011 Dec 27; 30(12):1320-6. PubMed ID: 21968130
    [Abstract] [Full Text] [Related]

  • 20. Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection.
    Waiser J, Budde K, Schütz M, Liefeldt L, Rudolph B, Schönemann C, Neumayer HH, Lachmann N.
    Nephrol Dial Transplant; 2012 Mar 27; 27(3):1246-51. PubMed ID: 21852274
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.